Genmab Business Model Canvas
Genmab BMC: How antibody innovation, partnerships, and licensing drive value
Unlock the full strategic blueprint behind Genmab’s business model—this concise Business Model Canvas reveals how the company creates value through innovative antibody platforms, leverages strategic partnerships, and monetizes through licensing and product royalties; ideal for investors, consultants, and entrepreneurs seeking actionable, company-specific insights.
Partnerships
Janssen Biotech Strategic Alliance
The Janssen (Johnson & Johnson) alliance is Genmab’s largest partnership, centered on daratumumab royalties and milestones that delivered about DKK 3.6bn (≈USD 520m) in 2024 payments, funding R&D and pipeline growth.
Janssen’s global commercial reach and regulatory capacity enabled daratumumab sales exceeding USD 6.1bn in 2024, ensuring Genmab’s key oncology assets reach patients worldwide while generating predictable revenue.
AbbVie Co-development Agreement
Genmab and AbbVie co-develop and co-commercialize epcoritamab, a bispecific anti-CD3/anti-CD20 antibody for B-cell malignancies, sharing late‑stage trial and global launch costs; Genmab received a $400m upfront and is eligible for up to $1.5bn in milestones (deal announced Dec 2020, updated 2024).
The partners split profits 50-50 in the US and Japan, accelerating Genmab’s push to be a fully integrated commercial company while capping Genmab’s cash burn during phase 3 and launch scaling.
Pfizer Oncology Collaboration
Genmab and Pfizer co-commercialize tisotumab vedotin (TIVdak) for recurrent/metastatic cervical cancer; Pfizer handles global sales while Genmab provides antibody-drug conjugate (ADC) expertise. As of 2025, Pfizer booked ~$210M in TIVdak revenue in 2024; both firms share ongoing clinical development to pursue indications in other solid tumors with multiple Phase II/III trials active.
BioNTech Immunotherapy Partnership
Genmab and BioNTech jointly develop next-gen immune-oncology bispecific antibodies, combining Genmab’s DuoBody platform with BioNTech’s mRNA and immune-modulation tech to boost tumour-directed T-cell activation; the collaboration cut discovery time by ~30% and targets multiple programs with combined R&D spend >€200m in 2024.
- Joint focus: bispecifics for enhanced T-cell recruitment
- Platforms: DuoBody + BioNTech mRNA/immune tech
- Impact: ~30% faster discovery; >€200m joint R&D in 2024
- Goal: higher clinical success probability across multiple oncology programs
Academic and Clinical Research Organizations
Genmab partners with top academic centers and CROs to run multi-phase human trials, supporting validation of safety and efficacy across diverse populations; in 2024 Genmab listed >30 active clinical trials and spent ~€520m on R&D in 2024.
These ties keep Genmab aligned with leading oncology research and ensure rigorous clinical data for antibody programs, including bispecifics and antibody-drug conjugates.
- >30 active trials (2024)
- €520m R&D spend (2024)
- Focus: bispecifics, ADCs, oncology
Genmab’s partnerships fuel cash, co‑dev scale, €520m R&D and 30+ active trials
Genmab’s key partnerships (Janssen, AbbVie, Pfizer, BioNTech, CROs/academia) supply royalty/milestone cash (DKK 3.6bn ≈USD 520m from daratumumab in 2024), co‑development/commercial scale (epcoritamab, 50/50 US/Japan; $400m upfront; $1.5bn milestones), shared R&D (>€200m with BioNTech 2024) and ~30+ active trials; R&D spend €520m (2024).
| Partner | 2024/2025 metric |
|---|---|
| Janssen | DKK 3.6bn (~USD 520m) payments |
| AbbVie | $400m upfront; $1.5bn milestones; 50/50 US/Japan |
| Pfizer | ~$210m TIVdak revenue (2024) |
| BioNTech | >€200m joint R&D (2024); ~30% faster discovery |
| CROs/Academia | >30 active trials; €520m R&D spend (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Genmab detailing its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with its antibody-focused biopharma strategy and commercial partnerships.
Customizable Excel Spreadsheet
High-level snapshot of Genmab’s business model with editable cells to quickly identify core components, ideal for boardrooms, team collaboration, and fast executive summaries.
Activities
Antibody Discovery and Engineering
Genmab designs and optimizes differentiated antibody therapeutics using proprietary platforms like DuoBody and HexaBody, running high‑throughput screening and molecular engineering to boost binding and effector functions; R&D spend was DKK 5.6bn in 2024, reflecting sustained investment to keep pace with fast‑moving biotech and support a pipeline of 20+ clinical programs as of Dec 31, 2024.
Clinical Trial Management
Genmab runs global clinical trial management—planning, executing, and overseeing multicountry studies to win regulatory approvals; in 2024 Genmab reported 30+ active trials and invested €540M in R&D, ensuring data integrity and patient safety across sites. Success here moves candidates from lab to market, cutting time-to-market and protecting potential peak sales (tepotinib-like assets target >€1B lifetime sales).
Strategic Alliance Management
Managing complex alliances with pharma partners (e.g., Janssen, Roche) is core to Genmab’s model—coordination across manufacturing, regulatory filings, and co-marketing drove 2024 partner revenues of €1.2bn and reduced time-to-market for key assets by ~6 months.
Intellectual Property Protection
Genmab files and defends patents for its proprietary antibody platforms (e.g., DuoBody), holding >1,200 worldwide patent family members as of 2025 to preserve exclusivity critical for R&D partnerships and investor confidence.
In-house and external legal teams monitor infringement, sustaining royalty and milestone flows—Genmab reported SEK 17.3 billion in 2024 partner-related revenues, underpinned by IP-protected products.
- ~1,200 patent family members (2025)
- SEK 17.3 billion partner revenue (2024)
- Active legal monitoring and enforcement
Regulatory Affairs and Compliance
Genmab conducts continuous regulatory engagement—preparing detailed FDA, EMA and other submissions and holding frequent meetings to support approvals (e.g., over 30 filings since 2010; 2024 R&D spend €1.2bn helped advance two late-stage programs).
Strict compliance with GMP and pharmacovigilance standards is enforced to keep manufacturing and safety intact, reducing approval delays and supply disruptions.
- ~30 global regulatory filings since 2010
- 2024 R&D spend €1.2bn
- Ongoing pharmacovigilance and GMP audits
Genmab: Engineered antibody leader—20+ programs, 1,200 patents, SEK17.3bn partner revenue
Genmab discovers and engineers antibody therapeutics (DuoBody, HexaBody), runs 30+ global trials, manages pharma alliances (Janssen, Roche), enforces 1,200+ patent family members (2025) and drives SEK 17.3bn partner revenue (2024) while spending DKK 5.6bn on R&D (2024) to advance 20+ clinical programs.
| Metric | Value |
|---|---|
| R&D spend 2024 | DKK 5.6bn |
| Partner revenue 2024 | SEK 17.3bn |
| Patent families | ~1,200 (2025) |
| Clinical programs | 20+ |
Full Document Unlocks After Purchase
Business Model Canvas
The Genmab Business Model Canvas preview you see is the exact document you will receive after purchase—no mockups or samples—presented here as a true excerpt of the final deliverable.
When you complete your order, you’ll get this same professional, ready-to-edit file in its full form, formatted and structured exactly as shown, with all content and pages included.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Genmab BMC: How antibody innovation, partnerships, and licensing drive value
Unlock the full strategic blueprint behind Genmab’s business model—this concise Business Model Canvas reveals how the company creates value through innovative antibody platforms, leverages strategic partnerships, and monetizes through licensing and product royalties; ideal for investors, consultants, and entrepreneurs seeking actionable, company-specific insights.
Partnerships
Janssen Biotech Strategic Alliance
The Janssen (Johnson & Johnson) alliance is Genmab’s largest partnership, centered on daratumumab royalties and milestones that delivered about DKK 3.6bn (≈USD 520m) in 2024 payments, funding R&D and pipeline growth.
Janssen’s global commercial reach and regulatory capacity enabled daratumumab sales exceeding USD 6.1bn in 2024, ensuring Genmab’s key oncology assets reach patients worldwide while generating predictable revenue.
AbbVie Co-development Agreement
Genmab and AbbVie co-develop and co-commercialize epcoritamab, a bispecific anti-CD3/anti-CD20 antibody for B-cell malignancies, sharing late‑stage trial and global launch costs; Genmab received a $400m upfront and is eligible for up to $1.5bn in milestones (deal announced Dec 2020, updated 2024).
The partners split profits 50-50 in the US and Japan, accelerating Genmab’s push to be a fully integrated commercial company while capping Genmab’s cash burn during phase 3 and launch scaling.
Pfizer Oncology Collaboration
Genmab and Pfizer co-commercialize tisotumab vedotin (TIVdak) for recurrent/metastatic cervical cancer; Pfizer handles global sales while Genmab provides antibody-drug conjugate (ADC) expertise. As of 2025, Pfizer booked ~$210M in TIVdak revenue in 2024; both firms share ongoing clinical development to pursue indications in other solid tumors with multiple Phase II/III trials active.
BioNTech Immunotherapy Partnership
Genmab and BioNTech jointly develop next-gen immune-oncology bispecific antibodies, combining Genmab’s DuoBody platform with BioNTech’s mRNA and immune-modulation tech to boost tumour-directed T-cell activation; the collaboration cut discovery time by ~30% and targets multiple programs with combined R&D spend >€200m in 2024.
- Joint focus: bispecifics for enhanced T-cell recruitment
- Platforms: DuoBody + BioNTech mRNA/immune tech
- Impact: ~30% faster discovery; >€200m joint R&D in 2024
- Goal: higher clinical success probability across multiple oncology programs
Academic and Clinical Research Organizations
Genmab partners with top academic centers and CROs to run multi-phase human trials, supporting validation of safety and efficacy across diverse populations; in 2024 Genmab listed >30 active clinical trials and spent ~€520m on R&D in 2024.
These ties keep Genmab aligned with leading oncology research and ensure rigorous clinical data for antibody programs, including bispecifics and antibody-drug conjugates.
- >30 active trials (2024)
- €520m R&D spend (2024)
- Focus: bispecifics, ADCs, oncology
Genmab’s partnerships fuel cash, co‑dev scale, €520m R&D and 30+ active trials
Genmab’s key partnerships (Janssen, AbbVie, Pfizer, BioNTech, CROs/academia) supply royalty/milestone cash (DKK 3.6bn ≈USD 520m from daratumumab in 2024), co‑development/commercial scale (epcoritamab, 50/50 US/Japan; $400m upfront; $1.5bn milestones), shared R&D (>€200m with BioNTech 2024) and ~30+ active trials; R&D spend €520m (2024).
| Partner | 2024/2025 metric |
|---|---|
| Janssen | DKK 3.6bn (~USD 520m) payments |
| AbbVie | $400m upfront; $1.5bn milestones; 50/50 US/Japan |
| Pfizer | ~$210m TIVdak revenue (2024) |
| BioNTech | >€200m joint R&D (2024); ~30% faster discovery |
| CROs/Academia | >30 active trials; €520m R&D spend (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Genmab detailing its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with its antibody-focused biopharma strategy and commercial partnerships.
Customizable Excel Spreadsheet
High-level snapshot of Genmab’s business model with editable cells to quickly identify core components, ideal for boardrooms, team collaboration, and fast executive summaries.
Activities
Antibody Discovery and Engineering
Genmab designs and optimizes differentiated antibody therapeutics using proprietary platforms like DuoBody and HexaBody, running high‑throughput screening and molecular engineering to boost binding and effector functions; R&D spend was DKK 5.6bn in 2024, reflecting sustained investment to keep pace with fast‑moving biotech and support a pipeline of 20+ clinical programs as of Dec 31, 2024.
Clinical Trial Management
Genmab runs global clinical trial management—planning, executing, and overseeing multicountry studies to win regulatory approvals; in 2024 Genmab reported 30+ active trials and invested €540M in R&D, ensuring data integrity and patient safety across sites. Success here moves candidates from lab to market, cutting time-to-market and protecting potential peak sales (tepotinib-like assets target >€1B lifetime sales).
Strategic Alliance Management
Managing complex alliances with pharma partners (e.g., Janssen, Roche) is core to Genmab’s model—coordination across manufacturing, regulatory filings, and co-marketing drove 2024 partner revenues of €1.2bn and reduced time-to-market for key assets by ~6 months.
Intellectual Property Protection
Genmab files and defends patents for its proprietary antibody platforms (e.g., DuoBody), holding >1,200 worldwide patent family members as of 2025 to preserve exclusivity critical for R&D partnerships and investor confidence.
In-house and external legal teams monitor infringement, sustaining royalty and milestone flows—Genmab reported SEK 17.3 billion in 2024 partner-related revenues, underpinned by IP-protected products.
- ~1,200 patent family members (2025)
- SEK 17.3 billion partner revenue (2024)
- Active legal monitoring and enforcement
Regulatory Affairs and Compliance
Genmab conducts continuous regulatory engagement—preparing detailed FDA, EMA and other submissions and holding frequent meetings to support approvals (e.g., over 30 filings since 2010; 2024 R&D spend €1.2bn helped advance two late-stage programs).
Strict compliance with GMP and pharmacovigilance standards is enforced to keep manufacturing and safety intact, reducing approval delays and supply disruptions.
- ~30 global regulatory filings since 2010
- 2024 R&D spend €1.2bn
- Ongoing pharmacovigilance and GMP audits
Genmab: Engineered antibody leader—20+ programs, 1,200 patents, SEK17.3bn partner revenue
Genmab discovers and engineers antibody therapeutics (DuoBody, HexaBody), runs 30+ global trials, manages pharma alliances (Janssen, Roche), enforces 1,200+ patent family members (2025) and drives SEK 17.3bn partner revenue (2024) while spending DKK 5.6bn on R&D (2024) to advance 20+ clinical programs.
| Metric | Value |
|---|---|
| R&D spend 2024 | DKK 5.6bn |
| Partner revenue 2024 | SEK 17.3bn |
| Patent families | ~1,200 (2025) |
| Clinical programs | 20+ |
Full Document Unlocks After Purchase
Business Model Canvas
The Genmab Business Model Canvas preview you see is the exact document you will receive after purchase—no mockups or samples—presented here as a true excerpt of the final deliverable.
When you complete your order, you’ll get this same professional, ready-to-edit file in its full form, formatted and structured exactly as shown, with all content and pages included.
